Literature DB >> 2602775

Pseudomonas bacteremia in a community teaching hospital, 1980-1984.

P G Gallagher1, C Watanakunakorn.   

Abstract

The epidemiologic characteristics, clinical course, and outcome of 96 episodes of pseudomonas bacteremia occurring during 1980-1984 in a community teaching hospital are reviewed. The male-to-female ratio for the patients involved was 1.9:1. The mean age was 64 years, and 41 patients were greater than or equal to 70 years of age. Sixty-two episodes were nosocomially acquired; nine were acquired in nursing homes. Twenty episodes were polymicrobial. The respiratory and genitourinary tracts were the most common sources of bacteremia. Seven patients had splenectomies prior to the onset of bacteremia. The overall mortality was 61%; mortality attributable to pseudomonas bacteremia was 48%. Statistically significant differences in mortality were related to underlying conditions and portal of entry. Findings in this series were compared with those in published series from different institutions over a period of years. Pseudomonas bacteremia remains a major infection in patients with underlying diseases and continues to cause high mortality in the 1980s.

Entities:  

Mesh:

Year:  1989        PMID: 2602775     DOI: 10.1093/clinids/11.6.846

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  10 in total

1.  Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990.

Authors:  F Vázquez; M C Mendoza; M H Villar; A Vindel; F J Méndez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Acute pneumonia and systemic lupus erythematosus.

Authors:  M V Sun; P J Kaplan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

3.  Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.

Authors:  Francine Kwee; Sandra A N Walker; Marion Elligsen; Lesley Palmay; Andrew Simor; Nick Daneman
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

4.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

5.  Pseudomonas aeruginosa selective adherence to and entry into human endothelial cells.

Authors:  M C Plotkowski; A M Saliba; S H Pereira; M P Cervante; O Bajolet-Laudinat
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition.

Authors:  A N Neely; R G Miller; I A Holder
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

8.  Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Authors:  B U von Specht; B Knapp; G Muth; M Bröker; K D Hungerer; K D Diehl; K Massarrat; A Seemann; H Domdey
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  The regulatory repertoire of Pseudomonas aeruginosa AmpC ß-lactamase regulator AmpR includes virulence genes.

Authors:  Deepak Balasubramanian; Lisa Schneper; Massimo Merighi; Roger Smith; Giri Narasimhan; Stephen Lory; Kalai Mathee
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 10.  Pathogen survival in the external environment and the evolution of virulence.

Authors:  Bruno A Walther; Paul W Ewald
Journal:  Biol Rev Camb Philos Soc       Date:  2004-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.